Survival from pancreatic cancer in England and Wales
Author Information
Author(s): Starling N, Cunningham D
Primary Institution: Royal Marsden Hospital
Conclusion
Survival rates for pancreatic cancer have not significantly improved over the years despite advances in diagnosis and treatment.
Supporting Evidence
- Only 10% of patients have potentially operable tumors confined to the pancreas.
- Improvements in diagnostic imaging have not significantly impacted overall survival trends.
- Gemcitabine is widely used as a first-line therapy but has only shown modest survival benefits.
Takeaway
Pancreatic cancer is really tough to treat, and even though doctors are getting better at finding it and helping patients, not many people are living longer after being diagnosed.
Methodology
The study analyzed survival rates and treatment outcomes for pancreatic cancer patients over different time periods.
Limitations
The study may not fully reflect improvements in survival due to the small number of patients who can have surgery.
Participant Demographics
The study included patients with pancreatic cancer in England and Wales, but specific demographics were not detailed.
Statistical Information
P-Value
0.0022
Statistical Significance
p=0.0022
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website